Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 1(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04918186Phase 2Recruiting

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Role: collaborator

NCT05271604Phase 2Completed

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Role: lead

NCT04681131Phase 2Completed

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Role: lead

NCT05808634Phase 1Recruiting

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Role: lead

NCT03425279Phase 1Completed

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Role: lead

NCT05180799Phase 1Active Not Recruiting

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Role: lead

NCT03504488Phase 1Completed

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Role: lead

All 7 trials loaded